Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Status:
Terminated

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.

Phase 2

Pfizer